Response Evaluation Criteria and Performance Scales

Article

In clinical studies, formal response criteria have been developed and have gained wide acceptance. The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST). In contrast, the World Health Organization (WHO) has a different standard for assessing response. Major differences between these guidelines are outlined below.

Recist: Definition of Response

In clinical studies, formal response criteria have been developed and have gained wide acceptance.

The National Cancer Institute (NCI) has proposed and implemented newer standard response criteria called Response Evaluation Criteria in Solid Tumors (RECIST).

In contrast, the World Health Organization (WHO) has a different standard for assessing response.

Major differences between these guidelines are outlined below.

Comparison of RECIST and WHO guidelines

Performance Scales

The Karnofsky performance index and WHO (Zubrod) scale are commonly used as proxy measures for quality of life.

Because they measure only one dimension of the construct, they would not be considered quality-of-life measures by today’s standards.

However, given their historic relevance and current high frequency of usage as proxy measures, we have included them here.

Karnofsky performance index and WHO (Zubrod) scale

Recent Videos
Retrospective and real-world registry studies may be necessary to guide clinical decision-making for rarer lymphomas with insufficient prospective data.
Extravasation results in exposing healthy tissue to radiation, which can be highly dosed depending on the isotope used for treatment.
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
Ongoing studies seek to evaluate immunotherapy in earlier lines of therapy for patients with early-stage Hodgkin lymphoma.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content